-
公开(公告)号：US20130095128A1
公开(公告)日：2013-04-18
申请号：US13638272
申请日：2011-03-30
IPC分类号： C07K7/06
CPC分类号： C07K7/06 , A61K39/0011 , A61K2039/572
摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.
摘要翻译： 衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留必需的HLA结合和/或CTL诱导性 的原始序列。 还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌 ，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。
-
公开(公告)号：US20120328638A1
公开(公告)日：2012-12-27
申请号：US13513543
申请日：2010-12-02
IPC分类号： A61K39/00 , C12N15/12 , A61P35/00 , C12N5/0783 , C12N5/0784 , C12N15/85 , C12N5/10 , C07K7/08 , A61K31/7088
CPC分类号： C07K14/82 , A61K39/0011 , C07K14/4748
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the MYBL2 gene that bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility, more particularly peptides having the amino acid sequence of SEQ ID NO: 5 and fragments thereof, are provided. The present invention further extends to peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, provided they retain cytotoxic T cell inducibility. Also provided as nucleic acids encoding any of the aforementioned peptides, antigen-presenting cells and isolated CTLs that target such peptides, and pharmaceutical agents and compositions including any of the aforementioned peptides, nucleic acids, and APCs as active ingredients. The components of the present invention have particular utility in connection with the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a postoperative recurrence thereof.
摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了衍生自结合HLA抗原并具有细胞毒性T淋巴细胞（CTL）诱导能力的MYBL2基因的表位肽，更特别是具有SEQ ID NO：5的氨基酸序列及其片段的肽。 本发明进一步扩展到包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加的肽，条件是它们保留细胞毒性T细胞诱导性。 还提供了编码任何上述肽，抗原呈递细胞和靶向这些肽的分离的CTL的核酸以及包含任何上述肽，核酸和APC作为活性成分的药物和组合物的核酸。 本发明的组分与癌症（肿瘤）的治疗和/或预防（即预防）和/或预防其术后复发有关。
-
公开(公告)号：US20120308591A1
公开(公告)日：2012-12-06
申请号：US13515656
申请日：2010-12-13
IPC分类号： A61K39/00 , C12N15/12 , C12N5/078 , C12N1/21 , C12N5/10 , A61K31/7088 , A61P35/00 , C12N15/63 , C07K7/06 , C12N15/85
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , A61K2039/57 , C07K14/705
摘要： Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.
摘要翻译： 描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段 这里。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。 本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。
-
公开(公告)号：US20120156231A1
公开(公告)日：2012-06-21
申请号：US13202078
申请日：2010-02-17
IPC分类号： A61K39/00 , C07K7/08 , C07K7/06 , C07H21/00 , C12N5/0783 , A61K48/00 , A61P37/04 , A61P35/00 , C12N5/078 , C12N15/85 , C07K14/47 , C12N15/12
CPC分类号： A61K31/7088 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K14/4748
摘要： The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 34 or fragments thereof, which bind to HLA antigen and induce cytotoxic T lymphocyte (CTL). The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances or compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances or compositions of the present invention may be used for treating cancer or tumor.
摘要翻译： 本发明提供了具有与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的具有SEQ ID NO：34或其片段的氨基酸序列的分离的肽。 本发明还提供了包括一个，两个或几个氨基酸插入，取代或加成上述肽或片段但仍具有细胞毒性T细胞诱导性的肽。 进一步提供了编码这些上述肽中的任何一种的核酸以及包含任何上述肽或核酸的药物或组合物。 本发明的肽，核酸，药物或组合物可用于治疗癌症或肿瘤。
-
公开(公告)号：US08735361B2
公开(公告)日：2014-05-27
申请号：US13141389
申请日：2009-12-17
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , C07K14/4748 , C12N2710/16222 , G01N33/57484 , G01N2333/47
摘要： The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 43 or immunologically active fragments thereof, which bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents and compositions of this invention may be used for treating cancer or tumor.
摘要翻译： 本发明提供具有与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导能力的具有SEQ ID NO：43的氨基酸序列或其免疫活性片段的分离的肽。 本发明还提供了包括一个，两个或几个氨基酸插入，取代或加成上述肽或片段但仍具有细胞毒性T细胞诱导性的肽。 还提供了编码任何这些上述肽的核酸以及包含任何上述肽或核酸的药剂和组合物。 本发明的肽，核酸，药物和组合物可用于治疗癌症或肿瘤。
-
公开(公告)号：US08617562B2
公开(公告)日：2013-12-31
申请号：US13202078
申请日：2010-02-17
CPC分类号： A61K31/7088 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K14/4748
摘要： The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 34 or fragments thereof, which bind to HLA antigen and induce cytotoxic T lymphocyte (CTL). The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances or compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances or compositions of the present invention may be used for treating cancer or tumor.
摘要翻译： 本发明提供了具有与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的具有SEQ ID NO：34或其片段的氨基酸序列的分离的肽。 本发明还提供了包括一个，两个或几个氨基酸插入，取代或加成上述肽或片段但仍具有细胞毒性T细胞诱导性的肽。 进一步提供了编码这些上述肽中的任何一种的核酸以及包含任何上述肽或核酸的药物或组合物。 本发明的肽，核酸，药物或组合物可用于治疗癌症或肿瘤。
-
公开(公告)号：US20120107333A1
公开(公告)日：2012-05-03
申请号：US13203939
申请日：2010-03-01
IPC分类号： A61K39/00 , C07H21/04 , C12N5/078 , A61P37/04 , A61K38/08 , C12N15/85 , C07K16/00 , C12N1/21 , C12N1/19 , C12N5/10 , C07K7/08 , A61P35/00
CPC分类号： C07K14/4748 , A61K39/00
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 35, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.
摘要翻译： 本发明提供分离的肽或衍生自SEQ ID NO：35的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。 肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。 本发明还提供包含这些肽的药物组合物。 本发明的肽可用于治疗癌症。
-
公开(公告)号：US20120003253A1
公开(公告)日：2012-01-05
申请号：US13141389
申请日：2009-12-17
IPC分类号： A61K39/00 , C12N15/12 , C07H21/00 , A61P37/04 , C12N5/10 , C12N5/0783 , A61P35/00 , C07K7/06 , C12N15/85
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , C07K14/4748 , C12N2710/16222 , G01N33/57484 , G01N2333/47
摘要： The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 43 or immunologically active fragments thereof, which bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents and compositions of this invention may be used for treating cancer or tumor.
摘要翻译： 本发明提供具有与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导能力的具有SEQ ID NO：43的氨基酸序列或其免疫活性片段的分离的肽。 本发明还提供了包括一个，两个或几个氨基酸插入，取代或加成上述肽或片段但仍具有细胞毒性T细胞诱导性的肽。 还提供了编码任何这些上述肽的核酸以及包含任何上述肽或核酸的药剂和组合物。 本发明的肽，核酸，药物和组合物可用于治疗癌症或肿瘤。
-
公开(公告)号：US20110200626A1
公开(公告)日：2011-08-18
申请号：US12997517
申请日：2009-06-10
IPC分类号： A61K39/00 , C12N15/87 , C12N5/0783 , C07K7/06 , C12N5/071 , A61K38/08 , C07H21/00 , A61K31/7088 , A61P35/00 , A61P37/04
CPC分类号： C07K14/4722 , A61K39/0011 , C07K7/06 , C07K14/4706
摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from IQGAP3 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 or HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the IQGAP3 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the IQGAP3 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, renal, esophageal, gastric, lung, breast, bladder and pancreatic cancer.
摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，本发明描述衍生自引起CTL的IQGAP3的表位肽。 本发明还提供了特异性识别用肽脉冲的HLA-A24或HLA-A02阳性靶细胞的已建立的CTL。 还提供了呈递任何肽的抗原呈递细胞和外来体以及诱导抗原呈递细胞的方法。 本发明还提供含有IQGAP3多肽或其编码的多核苷酸以及作为活性成分的外来体和抗原呈递细胞的药剂。 此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用 IQGAP3多肽，编码多肽的多核苷酸，呈递多肽的外来体或抗原呈递细胞，或本发明的药剂。 要靶向的癌症包括但不限于肾，食管，胃，肺，乳腺，膀胱和胰腺癌。
-
20.发明授权Method of inducing an immune response by administering WDRPUH epitope peptides 有权通过施用WDRPUH表位肽诱导免疫应答的方法公开(公告)号：US09115207B2
公开(公告)日：2015-08-25
申请号：US13900720
申请日：2013-05-23
IPC分类号： A61K38/04 , A61K38/08 , C07K14/47 , A61K39/00 , A61K38/17 , C12N5/0783 , C12N5/0784 , A61K38/00
CPC分类号： C07K7/06 , A61K38/00 , A61K38/1764 , A61K39/0011 , C07K14/47 , C07K14/4748 , C12N5/0638 , C12N5/0639
摘要： The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
摘要翻译： 本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽 ，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。 本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。 本发明的肽也可以用作疫苗。
-
-
-
-
-
-
-
-
-
搜索结果
34 条记录 (耗时 0.037 秒)
